Vaccine-maker IDT Biologika launches in US

By Fiona BARRY contact

- Last updated on GMT

Related tags: Tuberculosis

Attending yesterday's dedication ceremony (left to right), Maryland Department of Business and Economic Development Deputy Secretary Benjamin Wu, IDT Biologika Corporation President Ralf Pfirmann, City of Rockville Mayor Bridget Donnell Newton, and IDT Rockville Site Integration Leader Thomas Richter
Attending yesterday's dedication ceremony (left to right), Maryland Department of Business and Economic Development Deputy Secretary Benjamin Wu, IDT Biologika Corporation President Ralf Pfirmann, City of Rockville Mayor Bridget Donnell Newton, and IDT Rockville Site Integration Leader Thomas Richter
German CDMO IDT Biologika has opened its first facility in the US and will contract manufacture vaccines.

The vaccine manufacturing site in Rockville, Maryland will bridge pre-clinical and Phase II work, including process development, cell banking, cGMP manufacturing, purification and formulation, and fill and finish.

IDT Biologika will share the 75,000 sq ft facility, which meets BSL-2, US FDA, and EMA standards, with Aeras, a global non-profit developing tuberculosis vaccines. The two organisations will work together on process development and manufacturing of TB vaccine candidates.

With the new facility, we provide U.S. companies with a highly capable and experienced CMO-partner for phase I and phase II clinical vaccine projects right from the heart of the BioMaryland corridor,​” said President Ralf Pfirmann.

Acquisition

IDT Biologika GmbH is headquarted in Dessau-Rosslau and performs contract research and manufacturing for human and animal vaccines and biologics. It formed a subsidiary, IDT Biologika Corporation, which acquired the Maryland site in June from Aeras.

Maryland welcomed the German manufacturer to its state. Ben Wu, Deputy Secretary of the Maryland Department of Business and Economic Development, said “IDT Biologika’s decision to locate here is another example of how international companies are viewing Maryland as a prime location for their cutting-edge research and discoveries that are improving the lives of people across the globe.

“Our state is home to many vaccine, biotechnology and pharmaceutical companies, to renowned academic institutions, and to government agencies vital to the development of vaccines​.”

At a dedication ceremony yesterday, Pfirmann and Wu were joined by the Mayor of the City of Rockville, Bridget Donnell Newton, the CEO of Aeras, Jacqueline Shea, and representatives from Congress.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers